To uncover actionable molecular insights, transforming the odds so that our loved ones can overcome disease.
We are inexhaustible explorers
We are known for our perseverant, hard-working approach to molecular discoveries.
We are partners for progress
We help clients move their research forward through steadfast support, a detail-driven approach, and through operating as one team.
We are patient prioritizers
We treat the sample as the patient, and innovate testing for their better outcomes.
Meet the team
We bring hope to hard situations. When answers seem impossible, we are committed to finding a way forward.
President and CEO
Shinichi Sato is the President and CEO of Sysmex Inostics. Prior to this, he was Vice President of Project Management of Alliance, and Clinical Planning at Astex Pharmaceutical Inc., where he was responsible for the global oncology drug development strategy and go-to-market tactics involved in launching new initiatives and building and managing strategic partnerships.
Shinichi has over 30 years of experience in the pharma and diagnostics industries and specializes in post-merger integration. He also has an abundance of familiarity with global partnerships in the pharma industry and portfolio management in drug development.
Shinichi draws inspiration for what he does at Sysmex Inostics from the knowledge that, with every new diagnostic we successfully commercialize, there are potentially thousands of patients whose lives could be changed.
Outside the office, you can find him mountain climbing, traveling to historical places around the world, or listening to music on vinyl.
VP of Corporate Development
Yosuke is the VP for Corporate Development, where he is primarily focused on activities aimed at growing the company, including strategic partnerships and joint ventures. Yosuke has had a 20-plus-year career in the IT and advanced healthcare space, which has spanned multiple countries and continents, with extensive experience in the molecular diagnostics industry, building strategic alliances and leading mergers and acquisitions.
When he’s not hard at work trying to keep his finger on the pulse on the ever-evolving field of molecular diagnostics and digital health, you’ll find him out running around the Baltimore Inner Harbor.
Frederick S. Jones
Head of Medical Scientific Affairs
Frederick S. Jones
Dr. Jones is the head of Medical Scientific Affairs, where he leads a team to demonstrate the use and performance of diagnostic tests in real-world clinical settings and trials.
Fred has over 14 years of experience in the molecular diagnostics industry and was also a Professor at The Scripps Research Institute for 20 years, where he specialized in gene regulation and cellular mechanisms that control morphogenesis during embryonic development. He holds degrees from Yale and Rockefeller University, has co-authored over 100 publications, and has held several leadership positions in both academia and industry.
Fred is a liquid biopsy ambassador to the clinical world of physician-scientists; he deeply believes that biomarker testing at the right time can improve the care of or help cure cancer, and he spends his time spreading that message.
When he’s not knee-deep in clinical trials, you can find him sailing, surfing, camping, or raising his kids to think like scientists.
Aaron J. Lizee
VP of Commercial Operations
Aaron J. Lizee
Aaron is VP of Commercial Operations, overseeing global sales, account activities, business planning, partner alliance, information systems, and services to support Plasma-Safe-Seq and IVD development activities for Sysmex Inostics Germany (SIG) and Sysmex Corporation.
Aaron brings 18 years of experience in biotech, during which time he has worked in the life science, companion Dx, molecular Dx and pharma sectors, driving interest in next-generation sequencing (NGS) workflows, bioinformatics, enzyme engineering, microbiome, oncology, genetics, and molecular pathology. His knowledge and skill set spans from sales processes, project management, and marketing, along to developing, implementing, and launching products/services globally.
His inspiration for his work lies in seeing the technology he represents, empowering discoveries and decisions within the oncology landscape.
When he’s not building and managing relationships, you can find him hard at work creating one-of-a-kind woodwork pieces or designing beautiful custom pens.
Director of Finance
Jennifer is Director of Finance, where she oversees accounting and financial reporting operations and helps establish strategies to reduce cost and increase efficiency.
Jennifer, a Certified Public Accountant, has over 22 years of experience in accounting, including biotech, and is experienced in virtually all aspects of finance and accounting management from financial reporting, budgeting, financial modeling and analysis, business planning, and process improvement.
Her passion for the work she does is reignited every day by the positive attitudes and commitment of her co-workers and their focus on putting the patient first.
Director of QA/RA
Takeisha Farmer is the Director of QA/RA and is responsible for implementing, leading, and maintaining all Quality Assurance, Quality Management System, and Regulatory Affairs related activities. Her primary focus is to strategically position Sysmex Inostics quality and regulatory operations to aid in commercialization goals, ensuring continuous improvement and high-quality products and services enter emerging, regulated, and clinical global markets.
Takeisha started her career as a pharma CRO validation scientist. Since then, she has held various roles including Laboratory Accreditation Officer and Quality Manager across the clinical and medical device industries.
Takeisha’s passion for cancer diagnostics is largely inspired by and a tribute to her best friend, Roslyn, who lost her battle to breast cancer in 2011 at the age of 35. In her spare time, Takeisha is devoted to spending time with family, mentoring young professionals, taking long walks, and traveling.
Bernadette N. Owen, BS, MBA
Senior Manager, Projects
Bernadette N. Owen, BS, MBA
Bernadette is the Senior Manager, Projects, and is part of the Business Strategy team. She spends her time harmonizing projects at a corporate level, supporting and prioritizing initiatives to achieve our corporate vision. Bernadette is an AMA, certified project manager, and an ASQ, six sigma green belt with over 18 years of experience in biotech. She has brought regulated NGS products to market, managed government programs and coordinated complex international clinical trials, among other accomplishments.
Bernadette derives inspiration for her work from the knowledge that the organization’s core values include a focus on helping patients faced with a terrible life-impacting diagnosis.
When she’s not managing projects, Bernadette enjoys gardening, cycling along the C&O canal, or reading a good book.
Explore the lab
We care about every molecule and every detail, and we have a passion for discovery. We are intelligent and optimistic, and focus on lighting a way forward to support the future of health.
A lab like none other
A history of exploration and innovation.
BEAMing (OncoBEAM™) is developed as the first dPCR ctDNA technology (Liquid Biopsy).1
We formed Inostics to be the first Liquid Biopsy provider.
PSS is developed as the first UMI-based NGS Liquid Biopsy technology.2
Our CLIA lab is established to offer the first clinical Liquid Biopsy services for patients in 2013.
Sysmex acquires Inostics to add IVD expertise and global market access capabilities.
PSS is shown to have equivalent sensitivity to OncoBEAM3
BC-SEQ and RAS-RAF-SEQ become Sysmex Inostics’ first CLIA validated PSS testing services.
AML-MRD-SEQ shows promise for recurrence monitoring.4
HPV-SEQ and AML-MRD-SEQ are added to our Baltimore CLIA Lab’s test menu.
QIAGEN® becomes our CDx partner.
HPV-SEQ is proven to detect HPV 16 & 18 in the blood of patients5
NSCLC-SEQ has equivalent sensitivity to OncoBEAM.6
HNSCC-SEQ and AML-SEQ are added to our Test Menu.
HPV-SEQ is used to de-escalate treatment of HPV-driven cancer patients.7